STOCK TITAN

RTW Investments reports 6.1% Apellis (APLS) stake through advised funds

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

RTW Investments, LP and its managing partner Roderick Wong, M.D. reported beneficial ownership of Apellis Pharmaceuticals, Inc. common stock on a Schedule 13G. They report beneficial ownership of 7,666,764 shares of common stock, representing 6.1% of the outstanding class based on 126,525,218 shares outstanding as of October 23, 2025.

Both reporting persons have shared voting and shared dispositive power over these 7,666,764 shares, with no sole voting or dispositive power. The shares are held by certain funds advised by RTW Investments, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Apellis.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RTW Investments, LP
Signature:/s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D., Managing Partner
Date:02/17/2026
Roderick Wong
Signature:s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D.
Date:02/17/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

How much of Apellis Pharmaceuticals, Inc. (APLS) does RTW Investments own?

RTW Investments reports beneficial ownership of 7,666,764 Apellis shares, equal to 6.1% of the common stock. This percentage is based on 126,525,218 shares outstanding as of October 23, 2025, as disclosed in Apellis’ Form 10-Q.

Who are the reporting persons in this Apellis (APLS) Schedule 13G filing?

The filing is made by RTW Investments, LP and Roderick Wong, M.D.. RTW is the investment adviser to certain funds holding Apellis shares, and Dr. Wong is RTW’s Managing Partner and Chief Investment Officer, reporting shared beneficial ownership of the same shares.

Do RTW Investments and Roderick Wong control voting and disposition of Apellis (APLS) shares?

They report shared voting power and shared dispositive power over 7,666,764 Apellis shares, with zero sole voting or dispositive power. The shares are directly held by RTW-advised funds, and the reporting persons’ authority relates to those funds’ holdings.

Are Apellis (APLS) shares held by RTW intended to influence control of the company?

The filing certifies the Apellis shares were acquired and are held in the ordinary course of business. It further states they were not acquired and are not held for the purpose or effect of changing or influencing control of Apellis Pharmaceuticals, Inc.

Who receives dividends and sale proceeds from RTW’s Apellis (APLS) holdings?

The filing states that the RTW Funds have the right to receive, or direct the receipt of, dividends and proceeds from the sale of the Apellis shares reported. RTW Investments acts as investment adviser to these funds rather than holding the shares directly.

What type of filer is RTW Investments in this Apellis (APLS) Schedule 13G?

RTW Investments is identified as an investment adviser, and Roderick Wong is identified as a holding company/control person. The Schedule 13G structure reflects their roles in relation to the RTW Funds that directly own the Apellis common stock.